Vuzix Corporation (VUZI), our February pick at $6.15, closed at $7.55 yesterday for a gain of 23% in just over a month.

News of a development agreement with electronics giant Toshiba for customized smart glasses by Vuzix has resulted in some initial short covering and with a solid rise in volume and share prices. The agreement validates the patented waveguide technology Vuzix has that opens the way for augmented reality glasses that look like something you wouldn’t be embarrassed to wear. I test drove a working pair of the new Blade 3000 series of AR glasses (which will be rolled out the second half of this year) and they looked great, worked great, were surprisingly comfortable, lightweight, and sturdy.

Additionally, Vuzix was featured on the front page of the Wall Street Journal print edition on Sunday in an article titled “Smart Glasses Get a Fresh Look.”

And while the latest numbers show over 25% of the VUZI float short and still to cover, longs and shorts alike shouldn’t be surprised to see more positive news from VUZI on the Toshiba front.

CEO Paul Travers noted that:

“The (Toshiba) agreement demonstrates how we are leveraging and partnering our industry leading technology with top tier global partners.  We trust that this will be the first of many ongoing collaborations between the firms.”

 

Vuzix conference call Friday, March 17th at 9:00 am Eastern Time.

The call will cover Q4 and full-year 2016 financial results and provide a business update.

Dial-in Number for U.S. & Canadian Callers: 877-709-8150
Dial-in Number for International Callers (Outside of the U.S. & Canada): 201-689-8354

Participating on the call will be Vuzix Chief Executive Officer and President Paul Travers and Chief Financial Officer Grant Russell, who will discuss operational and financial highlights for the quarter and year ended December 31, 2016, and will share a business update.

A replay will be available for 30 days, starting on March 17, 2017, at approximately 10:30 a.m. (ET) by dialing 877-660-6853 within the U.S. or Canada, or 201-612-7415 for international callers. The conference ID# is 13656767.

Stay tuned VUZI longs, as all indications are that 2017 is going to be the breakout year for VUZI in sales, strategic partnerships, and investor awareness.


tapimmune-logoTapImmune (TPIV) to Host Inaugural Quarterly Business Update Conference Call and Webcast

TPIV is a more recent pick from two weeks ago at $4.30, see: TapImmune (TPIV): Developing Cutting-Edge Vaccines that Attack Ovarian and Breast Cancer with a Vengeance).

  • Loading stock data...

TapImmune’s current market cap of just $39 million is a bargain given the company’s cash balance + $13.3 million grant from the U.S. government, + four Phase II studies in progress with top tier partners like AstraZeneca (AZN) and Mayo Clinic.

TapImmune will have its inaugural quarterly business update conference call and live webcast today, Tuesday March 14th, at 4:30 pm Eastern Time.

You can register for the live webcast here: http://tapimmune.com/register/

  • To access the call, dial: (877) 870-4263 (U.S.), or (412) 317-0790 (International).
  • To access the live audio webcast, visit the Events section of the TapImmune website http://tapimmune.com/events/.

The webcast will be archived for 90 days beginning at approximately 6:30 p.m. ET, on March 14, 2017.


This should be an exciting call by TapImmune and I’ll be listening intently.

TPIV has 4 different phase 2 studies underway for breast and ovarian cancer with world-class sponsors and collaborative partners, and it’s very reasonable to expect continued share price appreciation as more retail and institutional investors become aware of the company in the coming weeks and months.

 

TapImmune Pipeline


See also: TapImmune January 2017 Investor Presentation.


Disclosure/Disclaimer/Terms of Use


Green Organic Dutchman - gary

Leave a reply

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> 

required